16522-55-7

Basic information

• Product Name: 2-FLUOROACRYLOYL CHLORIDE
• Synonyms: 2-FLUOROACRYLOYL CHLORIDE;2-Fluoropropenoyl chloride;2-FLUOROACRYLOYL CHLORIDE, 97% MIN.
• CAS NO: 16522-55-7
• Molecular Formula: C₃H₂ClFO
• Molecular Weight: 108.5
• Mol File: 16522-55-7.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 81.8 °C at 760 mmHg
• Flash Point: 3.3 °C
• Appearance: /
• Density: 1.248 g/cm³
• Vapor Pressure: 80.7mmHg at 25°C
• Refractive Index: 1.389
• Storage Temp.: Keep Cold
• CAS DataBase Reference: 2-FLUOROACRYLOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-FLUOROACRYLOYL CHLORIDE(16522-55-7)
• EPA Substance Registry System: 2-FLUOROACRYLOYL CHLORIDE(16522-55-7)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 16522-55-7(Hazardous Substances Data)

Usage

General Description

2-Fluoroacryloyl chloride is a chemical compound with the formula C3H2ClFO. It is an acyl chloride, meaning it contains a functional group composed of a carbonyl center linked to a chlorine atom. 2-FLUOROACRYLOYL CHLORIDE is used in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is a highly reactive and corrosive substance, and should be handled with caution due to its potential to cause skin and respiratory irritation. 2-Fluoroacryloyl chloride is also used in the production of polymers and other materials, but its use requires careful handling and proper ventilation to avoid exposure and adverse health effects.

InChI:InChI=1/C3H2ClFO/c1-2(5)3(4)6/h1H2

Upstream product

• 75-89-8 2,2,2-trifluoroethanol 
• 112753-67-0 α,β-Difluoropropionyl chloride 
• 430-99-9 2-fluoroacrylic acid 
• 112753-66-9 α-fluoro-β-chloropropanoyl chloride 
• 74893-46-2 2-fluoroprop-2-enoyloxysodium 

Relevant articles and documents

Direct Regio- and Diastereoselective Synthesis of δ-Lactams from Acrylamides and Unactivated Alkenes Initiated by RhIII-Catalyzed C?H Activation

We report a RhIII-catalyzed regio- and diastereoselective synthesis of δ-lactams from readily available acrylamide derivatives and unactivated alkenes. The reaction provides a rapid route to a diverse set of δ-lactams in good yield and stereoselectivity, which serve as useful building blocks for substituted piperidines. The regioselectivity of the reaction with unactivated terminal alkene is significantly improved by using Cpt ligand on the RhIII catalyst. The synthetic utility of the reaction is demonstrated by the preparation of a potential drug candidate containing a trisubstituted piperidine moiety. Mechanistic studies show that the reversibility of the C?H activation depends on the choice of Cp ligand on the RhIII catalyst. The irreversible C?H activation is observed and becomes turnover-limiting with [CptRhCl2]2 as catalyst.

Novel pyrimido-heterocyclic compound and preparation method and application thereof

The invention discloses a novel pyrimido-heterocyclic compound and a preparation method and application thereof. The structure of the pyrimido-heterocyclic compound disclosed by the invention is as shown in a general formula I, and the definitions of all substituents are described in the specification and claims. The pyrimido-heterocyclic compound disclosed by the invention has much better inhibitory activity and selectivity for double-mutant EGFR kinase than the existing AZD-9291, can be used for preparing anti-tumor drugs, and overcomes the defect of drug tolerance of the first generation ofEGFR inhibitor.

Quinoline and quinazoline derivatives, preparation method, intermediate, composition and use thereof (by machine translation)

The invention discloses a quinoline and quinazoline derivative I, a preparation method, an intermediate C, composition and an application. The preparation method comprises two methods, wherein the first method comprises steps as follows: 1, a compound A and a compound B react in a solvent under the action of alkali 1 to obtain a compound C; and 2, the product C obtained in the step 1 reacts with a compound D under the action of alkali 2; and the second comprises step as follows: the compound A and a compound E react in the solvent under the action of the alkali 1. The invention further provides the application of the compound represented in formula I or medicine composition in preparation of an EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor, an A431 or H1975 cell proliferation inhibitor or medicine for preventing or treating tumor diseases. The provided compound has better antitumor activity.